Metabolic Diseases  >>  Adlyxin (lixisenatide)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Adlyxin (lixisenatide) / Sanofi
NCT00299871 / 2006-002847-96: Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

Completed
2
542
US, Canada, Europe, RoW
LIXISENATIDE (AVE0010)
Sanofi
Type 2 Diabetes
08/07
08/07
NCT01175473 / 2009-017666-23: Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes

Checkmark IDF 2013
Oct 2013 - Oct 2013: IDF 2013
Checkmark
Feb 2013 - Feb 2013: 
Checkmark For type 2 diabetes at ADA 2012
More
Completed
2
148
Europe
Lixisenatide (AVE0010), Pen auto-injector, OptiClik®, Liraglutide, Pre-filled pen injector, Victoza®, Metformin
Sanofi
Type 2 Diabetes Mellitus
11/10
11/10
NCT01596504 / 2012-000027-40: Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin

Completed
2
142
Europe
Lixisenatide (AVE0010), Liraglutide, Victoza®, Insulin Glargine, Lantus® SoloSTAR®, Metformin
Sanofi
Type 2 Diabetes Mellitus
07/13
07/13
NCT01910194 / 2013-003171-35: Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying

Completed
2
39
Europe
Luyxumia versus Lantus
Profil Institut für Stoffwechselforschung GmbH, Sanofi
Diabetes Mellitus
10/14
10/14
NCT02274740 / 2014-002263-15: Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

Terminated
2
2
Europe
LIXISENATIDE AVE0010, metformin
Sanofi
Type II Diabetes Mellitus
08/15
08/15

Download Options